MCGLYNN MARGARET G
Known title: DirectorCIK: 0001215126
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Transaction History
| NVAX | ▲ Buy | Option Exercise | 18,880 | — | 6/20/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 10,420 | $0 | 6/12/2025 | View on chart |
| NVAX | ▲ Buy | Grant | 1,178 | $10K | 12/31/2024 | View on chart |
| NVAX | ▲ Buy | Grant | 778 | $10K | 9/30/2024 | View on chart |
| NVAX | ▲ Buy | Grant | 713 | $10K | 6/30/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 6,670 | $0 | 6/12/2024 | View on chart |
| NVAX | ▲ Buy | Grant | 2,029 | $10K | 3/31/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,100 | — | 6/10/2023 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 700 | — | 6/17/2022 | View on chart |
| VRTX | ▼ Sell | Other | 921 | — | 5/1/2022 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 5,000 | $638K | 4/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,900 | $1.4M | 4/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 100 | $28K | 4/8/2022 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 5,000 | $638K | 3/31/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,970 | $779K | 3/31/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,011 | $266K | 3/31/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,019 | $266K | 3/31/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 212 | $52K | 1/28/2022 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 5,000 | $638K | 1/28/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,901 | $457K | 1/28/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 800 | $193K | 1/28/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,087 | $507K | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.